Grail Stock Plunges 49% After Earnings. Test Results Are to Blame.
Grail's stock significantly dropped after the company reported disappointing trial results for its Galleri blood test, a cancer detection tool. The biotech company experienced its largest single-day percentage decrease on record following this news related to its earnings.
Grail Stock Plunges 50% After Earnings. But It’s These Test Results That Are to Blame.
Grail stock experienced a significant 50% plunge in after-hours trading following the release of disappointing cancer trial results. While the decline occurred after earnings, the specific test results from its Galleri blood test, designed to screen for various cancers, are identified as the primary reason for the investor dissatisfaction.
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Grail, Inc. (NASDAQ: GRAL) after the company's shares dropped significantly following the disclosure that its NHS-Galleri trial failed to meet its primary clinical endpoint. The law firm is inviting affected shareholders to join its investigation to explore the possibility of recovering their losses under federal securities laws.
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of Grail, Inc. (NASDAQ: GRAL) investors following a significant stock decline. The investigation was prompted by Grail's disclosure that its NHS-Galleri trial failed to meet its primary clinical endpoint, causing a 48% drop in after-hours trading. Johnson Fistel is examining whether Grail complied with federal securities laws and encourages affected shareholders to contact them regarding potential recovery of losses.
GRAL Stock Slumps 48% After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses
GRAIL Inc. (GRAL) shares plummeted 48% after hours following the announcement that its Galleri multi-cancer screening trial in England failed to meet its primary endpoint of significantly reducing late-stage cancer diagnoses. While the overall trial did not achieve statistical significance, GRAIL noted a favorable trend in reducing Stage III-IV cancers within a pre-specified group of 12 deadly cancers and highlighted a four-fold improvement in overall cancer detection rate compared to standard care. The company reported a 14% increase in Q4 revenue to $43.6 million, exceeding analyst estimates, amidst a net loss of $99.2 million.
(GRAL) Movement as an Input in Quant Signal Sets
This article analyzes Grail Inc Com (NASDAQ: GRAL), highlighting divergent sentiment across all time horizons and an exceptional 77.6:1 risk-reward setup. It outlines three AI-generated institutional trading strategies: a position trading strategy, a momentum breakout strategy, and a risk-hedging strategy, each with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for near-term, mid-term, and long-term outlooks.
GRAIL, Inc (GRAL) Tops Q4 2025 Earnings Estimates — EPS $-2.46 vs $-3.26 Expected
GRAIL, Inc (GRAL) beat its Q4 2025 earnings estimates, reporting an EPS of $-2.46 against an expected $-3.26, a 24.7% surprise. The company's revenue for the quarter reached $141.8M, and its shares saw a 6.0% increase in after-hours trading to $106.04. A detailed analysis is expected to follow.
Assessing GRAIL (GRAL) Valuation After Galleri PMA Milestone And Strong Clinical Data Progress
GRAIL (GRAL) has submitted the final module of its Premarket Approval application for the Galleri multi-cancer early detection test to the U.S. FDA. While the stock has seen recent pullbacks, longer-term momentum remains strong, and analysts view GRAIL as undervalued with a fair value of $115, driven by anticipated FDA approval and broad payer reimbursement. However, the company's high P/S ratio and sustained net losses present risks to this optimistic outlook.
GRAIL, Inc. (GRAL) Stock Analysis: 17.95% Potential Upside in the Healthcare Diagnostics Sector
GRAIL, Inc. (GRAL), a healthcare diagnostics company, shows a potential upside of 17.95%, with analysts setting a target price range between $105.00 and $130.00. Despite impressive revenue growth of 26.30%, the company faces financial challenges, including a negative EPS and free cash flow, indicating a focus on expansion. GRAIL's innovative cancer detection products, such as Galleri, position it strongly in the market, attracting optimistic sentiment from analysts despite current financial hurdles.
Baird initiates Grail stock coverage with Outperform on cancer test
Baird has initiated coverage on Grail, Inc. (NASDAQ:GRAL) with an Outperform rating and a $113 price target, citing potential catalysts like the NHS-Galleri study readout and an FDA decision. The company, focused on multi-cancer early detection, has shown strong revenue growth but is not yet profitable. This follows recent positive preliminary Q4 and full-year 2025 results that led Canaccord Genuity to reiterate its Buy rating and raise its price target to $105.
GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
GRAIL, Inc. announced it will release its fourth quarter and full year 2025 financial results after the market closes on Thursday, February 19, 2026. Following the release, company management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and business progress. Interested parties can access the live webcast and recorded replay via GRAIL’s investor relations website.
GRAIL Inc (GRAL) Shares Up 5.15% on Feb 10
GRAIL Inc (GRAL) shares rose 5.15% to $105.57 on February 10, placing the stock significantly above its 52-week low. Wall Street analysts have an average target price of $105.00 for GRAL, with a consensus "Outperform" recommendation. This report was generated using automated technology and GuruFocus financial data.
GRAIL, Inc. (GRAL) Stock Analysis: Healthcare Innovator With Potential 14.54% Upside
GRAIL, Inc. (GRAL) is highlighted as a healthcare innovator with a $3.91 billion market cap, specializing in multi-cancer early detection through products like Galleri. Despite not yet being profitable with a negative P/E and ROE, the company shows strong revenue growth of 26.30%. Analysts offer a cautiously optimistic view, projecting a potential upside of 14.54% for investors willing to undertake the associated risks.
GRAIL submits FDA PMA for Galleri multi-cancer early detection test
GRAIL has submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri multi-cancer early detection test. This submission marks a significant step towards potentially making a blood test for early cancer detection more widely available. The Galleri test is designed to detect more than 50 types of cancer, many of which lack routine screening programs.
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia
Samsung C&T and Samsung Electronics have entered into a strategic collaboration with GRAIL, Inc. to introduce GRAIL’s Galleri multi-cancer early detection test to key markets in Asia. Alongside this partnership, Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per share. This collaboration aims to leverage GRAIL's technology to detect cancer earlier, enhancing the potential for successful treatment.
Moloney Securities Asset Management LLC Has $959,000 Stock Holdings in GRAIL, Inc. $GRAL
Moloney Securities Asset Management LLC significantly reduced its stake in GRAIL, Inc. (NASDAQ:GRAL) by 59.6% in the third quarter, now holding 16,216 shares valued at $959,000. Despite this, several other institutional investors, including Geode Capital Management, Allianz Asset Management, and Invesco Ltd., substantially increased their holdings in GRAIL. Analysts currently give GRAIL an average "Hold" rating with an average target price of $105.00.
GRAIL, Inc. $GRAL Shares Purchased by Allianz Asset Management GmbH
Allianz Asset Management GmbH significantly increased its stake in GRAIL, Inc. (NASDAQ:GRAL) during the third quarter, purchasing an additional 174,959 shares, bringing its total holdings to 294,835 shares valued at approximately $17.43 million. GRAIL reported better-than-expected Q3 earnings per share and revenue, though it remains unprofitable. Analyst opinions are mixed but several have raised their price targets for the biotechnology company.
What GRAIL (GRAL)'s FDA PMA Submission for Galleri Test Means For Shareholders
GRAIL, Inc. (GRAL) has submitted the final module of its Premarket Approval application to the FDA for its Galleri multi-cancer early detection test, a significant step following its Breakthrough Device designation. This submission, backed by extensive clinical trial data, shifts the investment focus from "will they file?" to "how will the FDA respond?", emphasizing regulatory risk for a company that remains unprofitable with a high sales multiple. Investors should consider diverse fair value estimates and potential regulatory review timelines as crucial factors influencing GRAIL's future performance and valuation.
Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time.
Hims & Hers is promoting a new cancer screening blood test called Galleri, developed by Grail, which screens for over 50 types of cancer. The company featured this test in a recent Super Bowl ad, alongside its weight loss and testosterone treatments. However, this early cancer detection test is considered controversial by some medical experts.
What GRAIL (GRAL)'s FDA PMA Submission for Galleri Test Means For Shareholders
GRAIL, Inc. has completed the FDA Premarket Approval (PMA) submission for its Galleri multi-cancer early detection test, a significant regulatory milestone backed by data from the PATHFINDER 2 and NHS-Galleri trials. This submission shifts investor focus from the question of filing to how the FDA will respond, emphasizing regulatory risk and timelines. While strengthening GRAIL's investment narrative, the company remains unprofitable with a high sales multiple and its valuation faces potential challenges depending on the FDA's review process.
Hims & Hers Launches GRAIL Multi Cancer Screening Test
Hims & Hers Health (HIMS) shares rose after the company announced it will offer GRAIL Inc.'s Galleri multi-cancer detection test through its platform. This partnership provides a blood-based cancer screening option to Hims & Hers Labs subscribers, aiming to make early detection more accessible and expand the company's digital health offerings beyond telemedicine. The test screens for over 50 cancer types but is not diagnostic.
Hims & Hers Launches GRAIL Multi Cancer Screening Test
Hims & Hers Health (HIMS) has announced a partnership to offer GRAIL Inc.'s Galleri multi-cancer detection test through its Labs plan, leading to a nearly 15% jump in its premarket shares. This move allows subscribers to access a blood-based test for over 50 cancer types before symptoms appear, with a $250 discount, aligning with the company's goal to expand beyond telemedicine and make early detection more accessible. The test is recommended for adults at higher cancer risk and signifies a strategic shift towards becoming a broader digital health platform.
GRAIL submits FDA PMA for Galleri multi-cancer early detection test
The article states that GRAIL has submitted a Premarket Approval (PMA) application to the FDA for its Galleri multi-cancer early detection test. This submission marks a significant step towards the potential widespread availability of a blood test that can screen for multiple types of cancer before symptoms appear. This indicates progress in the field of early cancer detection technology.
Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care
Hims & Hers Health, Inc. has launched access to the Multi-Cancer Test by Galleri®, an innovative blood test from GRAIL, Inc. that can screen for over 50 types of cancer before symptoms appear. This initiative aims to make proactive cancer screening more accessible, especially for aggressive cancers often detected at later stages. By partnering with GRAIL, Hims & Hers seeks to empower individuals to take control of their health with cutting-edge technology.
Hims adds cancer detection test to Labs product
Hims & Hers is expanding its Labs product by adding Galleri, a cancer detection blood test from Grail, which screens for over 50 types of cancer before symptoms appear. The test will be offered at a discount to Labs subscribers and is part of Hims' strategy to pivot away from weight-loss treatments, with its Labs product featuring prominently in an upcoming Super Bowl ad. Grail, which has received investment from Hims, also recently filed for FDA approval for its Galleri test, aiming for broader insurance coverage.
GRAIL, Inc. (GRAL) Investor Outlook: A Healthcare Innovator With 10.93% Upside Potential
GRAIL, Inc. (GRAL) is a healthcare innovator focusing on multi-cancer early detection technology, with its flagship product Galleri. Despite current financial challenges like negative EPS and free cash flow, indicating significant investment in R&D, the company shows strong revenue growth and positive technical indicators. With 2 buy and 2 hold ratings from analysts and a 10.93% upside potential, GRAIL presents an opportunity for investors interested in high-growth healthcare innovation.
GRAIL, Inc.'s (NASDAQ:GRAL) Institutional Investors Lost 13% Over the Past Week but Have Profited From Longer-term Gains
Institutional investors in GRAIL, Inc. (NASDAQ:GRAL) experienced a 13% loss over the past week, though they have seen a substantial 220% return over the last year. Institutions hold approximately 60% of the company's shares, indicating significant influence over stock price movements and making their preferences important for the board. The article also highlights insider ownership and the general public's 24% stake, while advising readers to consider analyst sentiments and potential future developments.
GRAIL (GRAL) Is Down 13.0% After Final PMA Module Filing for Galleri Multi-Cancer Test
GRAIL (GRAL) shares dropped 13.0% after the company filed the final module of its Premarket Approval application for the Galleri multi-cancer early detection test with the FDA. This filing is a significant regulatory milestone and could influence the company's investment narrative, although concerns remain regarding cash burn, losses, and potential dilution. The stock's current valuation is seen as rich, and there's a wide range of fair value estimates among investors.
Trifecta Capital Advisors LLC Purchases 10,250 Shares of GRAIL, Inc. $GRAL
Trifecta Capital Advisors LLC significantly increased its stake in GRAIL, Inc. by 89.9%, purchasing an additional 10,250 shares to now own 21,650 shares valued at approximately $1.28 million. GRAIL, a biotechnology company focused on early cancer detection, reported quarterly EPS of -$2.46, beating estimates, and revenue of $36.19 million. Despite mixed analyst ratings, the consensus target price for GRAIL is set at $105.00.
GRAIL Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Blood Test
GRAIL has submitted a Premarket Approval application to the FDA for its Galleri multi-cancer early detection blood test. This submission, supported by data from large US and UK studies (PATHFINDER 2 and NHS-Galleri trial), aims for Galleri to complement existing cancer screenings. If approved, Galleri would be the first multi-cancer early detection test authorized for population screening in the US.
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test
GRAIL has submitted the final module of its premarket approval (PMA) application to the FDA for its Galleri multi-cancer early detection (MCED) test. This submission, which includes data from the U.S. PATHFINDER 2 study and the NHS-Galleri trial, seeks to expand access to the test, potentially transforming early cancer detection and public health outcomes. The company's shares have risen significantly over the past six months, reflecting strong investor confidence in its potential market impact.
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. has submitted its Premarket Approval (PMA) application to the FDA for its Galleri multi-cancer early detection (MCED) test, which received Breakthrough Device designation in 2018. The submission builds on data from the PATHFINDER 2 study and the NHS-Galleri trial, aiming to provide a significant public health benefit by detecting cancer earlier. The Galleri test seeks to improve current cancer screening programs, as cancer is the leading cause of death for adults over 50 in the U.S.
Assessing GRAIL (GRAL) Valuation After Analyst Upgrades And Strong Recent Shareholder Returns
GRAIL (GRAL) has seen recent analyst upgrades and strong share price performance, with a 1-year return of 278.77%, driven by growing interest in its multi-cancer early detection platform. While a narrative fair value suggests the stock is 3.8% undervalued at $105, a DCF model estimates a much lower fair value of $27.47, highlighting different long-term assumptions. The company's valuation depends heavily on the success of clinical readouts, such as the NHS Galleri study, and its ability to manage cash burn and losses.
Why (GRAL) Price Action Is Critical for Tactical Trading
This article provides an in-depth analysis of Grail Inc Com (NASDAQ: GRAL) stock, highlighting strong sentiment across all horizons and an exceptional risk-reward short setup. It details institutional trading strategies, including position, momentum, and risk-hedging strategies, supported by multi-timeframe signal analysis and AI-generated signals. The report emphasizes the critical nature of GRAL's price action for tactical trading decisions.
Beyond The Numbers: 4 Analysts Discuss GRAIL Stock
Four analysts have provided ratings for GRAIL (NASDAQ: GRAL) in the last quarter, with an average price target of $111.25, reflecting a 23.61% increase from the prior average. The company, focused on early cancer detection, shows positive revenue growth but lags behind peers in its sector, while demonstrating strong net margins and conservative debt management. Analysts' assessments are crucial for investors seeking insights into GRAIL's market standing and future prospects.
Canaccord Genuity reiterates Buy rating on GRAIL stock with $105 target
Canaccord Genuity has reiterated its Buy rating and $105 price target on GRAIL, Inc. (NASDAQ:GRAL) after the company's Q4 and FY2025 results exceeded analyst estimates, driven by a 35% year-over-year growth in Galleri testing volume. Despite operating with negative gross profit margins and not expecting profitability this year, GRAIL reported strong revenue growth, a solid cash position, and anticipates future growth from FDA submission, commercial penetration, and data readouts. The stock's current valuation reflects investor optimism surrounding these catalysts.
GRAIL Stock (-9.6%) : Guidance Disappoints + Valuation Reset
This article reports a 9.6% drop in GRAIL stock due to disappointing guidance and a subsequent valuation reset. The content primarily focuses on Trefis platform navigation elements and disclaimers about financial market data rather than providing specific details on GRAIL's performance or outlook. It mentions consensus EPS estimates from QuoteMedia and data delay information for various stock exchanges.
No News JSON Data Available
GRAIL Inc.'s stock (NASDAQ: GRAL) saw a 14.83% increase, driven by positive sentiment surrounding FDA designations. Despite this surge, a deeper look reveals financial struggles, including negative EBIT and pretax profit margins, and issues with free cash flow, though debt-to-equity is low. The article emphasizes that while current market dynamics are influenced by investor sentiment, future success for GRAIL depends on internal efficiencies and strategic clarity to overcome profitability challenges.
Does GRAIL’s 2025 Revenue Guidance Clarify Its Long-Term Growth Narrative For Investors (GRAL)?
GRAIL, Inc. has issued 2025 revenue guidance of US$147 million to US$148 million, indicating 17% to 18% growth over 2024. This guidance aims to provide clarity on the company's commercial trajectory and supports its long-term investment narrative, which centers on its multi-cancer early detection platform. While the guidance moderates some earlier growth forecasts, it reinforces the story of continued adoption, though risks like unprofitability and funding needs persist.
GRAIL (NASDAQ:GRAL) Trading Up 8.4% - Still a Buy?
GRAIL (NASDAQ:GRAL) stock saw an 8.4% increase on Tuesday, trading at $104.85, surpassing the consensus price target. The company achieved better-than-expected earnings and revenue last quarter, though it remains unprofitable. Analyst ratings are mixed but the overall consensus is a "Hold" with a target price of $97.50.
GRAL Shares Surge as Market Awaits Major Strategic Announcements
GRAIL Inc. (GRAL) stock has surged by 4.77%, driven by anticipation of strategic announcements, including a potential partnership or acquisition, and investor enthusiasm for its AI integration and cost-cutting initiatives. Despite significant profitability challenges reflected in negative margins, the company boasts strong liquidity and low debt, aiming for operational improvements and revenue diversification. The market is closely watching GRAL's transformation as it seeks to redefine its industry standing through technological advancements and strategic repositioning.
GRAIL Inc (GRAL) Shares Up 4.37% on Jan 20
GRAIL Inc (GRAL) shares rose by 4.37% on January 20, reaching an intraday high of $102.99 before closing at $100.93. This places the stock significantly above its 52-week low. Wall Street analysts maintain an "Outperform" status for GRAL, with an average price target of $105.00, implying a 4.04% upside from its current price.
Understanding Momentum Shifts in (GRAL)
This article analyzes Grail Inc Com (NASDAQ: GRAL), highlighting strong sentiment across all time horizons and an exceptional risk-reward setup. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also provides multi-timeframe signal analysis with support and resistance levels for near, mid, and long-term traders.
GRAIL Inc (GRAL) Shares Gap Down to $99.95 on Jan 15
GRAIL Inc (GRAL) shares dropped 4.58% to $99.95 on January 15, reaching an intraday low of $99.00 before slightly recovering. The stock is currently 13.66% below its 52-week high but 503.56% above its 52-week low. Analysts have an average target price of $105.00, implying a 5.05% upside, and the company holds an "Outperform" average brokerage recommendation.
GRAIL (NASDAQ:GRAL) Trading Down 5.7% - Time to Sell?
GRAIL (NASDAQ:GRAL) saw its stock price drop 5.7% on Thursday, trading at $98.73 on significantly lower volume than average. Analyst sentiment toward the company is mixed, with two "Buy," one "Hold," and one "Sell" rating, resulting in a consensus "Hold" rating and an average price target of $97.50. The biotech company, known for its Galleri multi-cancer blood test, continues to report negative profitability but beat EPS estimates in its last quarter.
Commonwealth Equity Services LLC Sells 37,220 Shares of GRAIL, Inc. $GRAL
Commonwealth Equity Services LLC decreased its stake in GRAIL, Inc. by 19.9% in Q3, selling 37,220 shares but still owning 150,264 shares valued at $8.9 million. This sale comes amidst other institutional investor activity and notable insider selling from GRAIL's CEO and President. Despite Q3 earnings beating analyst estimates, GRAIL remains unprofitable, and analysts have a mixed "Hold" consensus with a target price below the current trading value.
Does Morgan Stanley’s Hold on GRAIL (GRAL) Reframe Expectations for Galleri’s Path to Profitability?
Morgan Stanley initiated coverage on GRAIL (GRAL.US) with a hold rating and a US$110 target, suggesting a neutral outlook on the company's multi-cancer early detection business, Galleri. The analyst rating comes amid positive interim clinical data for Galleri but doesn't alleviate concerns about GRAIL's ongoing net losses and cash burn. Investors are encouraged to weigh emerging clinical evidence against financial risks and consider multiple perspectives on the stock's potential.
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle
Illumina has reported preliminary 2025 revenue and EPS that exceeded its guidance, achieving midteens earnings growth. The company continues to lead in genomic sequencing, focusing on transforming human health through its instruments and consumables. These positive results help distance Illumina from the financial implications of the Grail acquisition.
Canaccord Genuity reiterates Buy rating on GRAIL stock after strong results
Canaccord Genuity has reiterated a Buy rating on GRAIL (NASDAQ: GRAL) stock and reaffirmed its $105.00 price target after the company reported strong preliminary fourth-quarter and full-year 2025 results. GRAIL's results exceeded analyst estimates, driven by a 35% year-over-year growth in Galleri testing volume for 2025 and an optimistic revenue guidance for 2026. Despite the stock potentially being overvalued at its current price, investors have seen a substantial 470% return over the past year, with further potential catalysts like FDA submission and Medicare coverage on the horizon.
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia
Samsung C&T and Samsung Electronics have partnered with GRAIL, Inc. to introduce GRAIL’s Galleri multi-cancer early detection test to key Asian markets. The Samsung entities will also invest $110 million into GRAIL, a company focused on early cancer detection. This collaboration aims to enhance cancer detection capabilities in Asia.
